胸主动脉壁内血肿:单中心12年经验
回顾性分析2007年7月至2020年7月单中心54例壁内血肿(厚度≥7 mm)患者,其中Stanford A型24例(初始手术10例、初始药物治疗14例,后者2例后续手术),B型30例均初始药物治疗(3例后续手术)。三组长期生存无差异,平均随访22.8个月;药物治疗者随访影像可见部分完全吸收,但动脉瘤形成并不少见。
要点
- A型壁内血肿初始药物治疗者中2例后续转手术,B型初始药物治疗者中3例后续手术。
- 药物治疗者末次随访影像示A型36%、B型31%完全吸收,分别于3.7和31.5个月。
- 三组平均随访22.8个月长期生存无差异,但壁内血肿部位或其他节段动脉瘤总体发生率为50%。
核心结论
- 作者认为,对经过适当选择的A型壁内血肿患者,采用抗冲动治疗的药物治疗似乎有一席之地。
- 这类患者需在短期和长期密切临床与影像随访以发现恶化征象。
- 采用该方案,其长期生存可与手术治疗的A型及药物治疗的B型壁内血肿患者相似,但可能需晚期手术干预,尤其是动脉瘤病变。
研究设计与样本
- 单中心回顾性分析本院数据库,纳入2007年7月至2020年7月计算机断层扫描报告识别的壁内血肿厚度≥7 mm患者。
- 排除与创伤、既往主动脉手术、穿透性粥样硬化性溃疡、内膜片或医源性来源直接相关的壁内血肿,以及就诊时从未接受任何壁内血肿治疗者。
- 共54例符合纳入和排除标准:Stanford A型24例(初始手术10例、初始药物治疗14例,其中2例后续手术);B型30例均初始药物治疗,其中3例最终需手术干预。
主要发现
- 院内生存率:A型手术治疗90%,A型药物治疗93%,B型药物治疗97%。
- 药物治疗患者末次随访影像:A型36%、B型31%在未手术情况下壁内血肿完全吸收,分别为3.7个月和31.5个月。
- 原壁内血肿部位动脉瘤形成:A型药物治疗队列18%(2/11),B型药物治疗队列12%(3/26)。
- 壁内血肿区域或其他节段动脉瘤总体发生率为50%。
- 平均随访22.8个月,三个队列长期生存无差异。
临床怎么用
- 作者认为,对经过适当选择的A型壁内血肿患者,抗冲动治疗的药物治疗似乎有一席之地。
- 作者提出这类患者需在短期和长期密切临床与影像随访以发现恶化征象。
- 作者指出这类患者可能需晚期手术干预,尤其是动脉瘤病变。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The natural history and management of intramural hematoma (IMH) has varied significantly worldwide. From the present retrospective analysis of our institutional database, we have reported the long-term results from medical and surgical management of types A and B IMH. METHODS: Computed tomography reports completed at our tertiary care hospital from July 2007 to July 2020 were used to identify patients with IMH with a thickness of ≥7 mm. Those with IMH directly related to trauma, previous aortic surgery, penetrating atheromatous ulcer, dissection flap, or an iatrogenic source and those who had never received any treatment of IMH at presentation were excluded. RESULTS: A total of 54 patients with IMH had met the inclusion and exclusion criteria. Of the 54 patients, 24 had presented with Stanford type A. Of these 24 patients, 10 had initially undergone surgery and 14 had initially received medical treatment. Two patients in the medical group had subsequently undergone surgery. In addition, 30 patients had presented with type B IMH and had initially received medical treatment, with 3 eventually requiring surgical intervention. In-hospital survival was 90% for type A IMH treated surgically, 93% for type A IMH treated medically, and 97% for type B IMH treated medically. At the last follow-up imaging study of the medically treated patients, 36% of those with type A IMH and 31% of those with type B IMH had experienced complete resolution of IMH at 3.7 and 31.5 months respectively, without surgical intervention. The development of an aortic aneurysm at the site of a previous IMH had occurred in 18% (2 of 11) and 12% (3 of 26) of the type A medical and type B medical cohorts. The overall rate of aortic aneurysm formation in the region of IMH or in another segment was 50%. No difference was found in long-term survival between the three cohorts at a mean follow-up of 22.8 months. CONCLUSIONS: A role appears to exist for medical treatment with anti-impulse therapy for appropriately selected patients with type A IMH. These patients must be followed up closely clinically and radiographically for signs of deterioration in the short- and long-term phases of their care. They can achieve long-term survival similar to that of surgically treated type A IMH and medically treated type B IMH patients using this algorithm. However, they might require late surgical intervention, especially for aneurysmal disease.
引用
- Abdu RW, Long GW, Baker D, et al. Intramural hematoma of the thoracic aorta: A single-institution, 12-year experience. J Vasc Surg. 2022. PMID: 35066059. doi:10.1016/j.jvs.2021.12.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。